钙增敏剂——Levosimendan在抗心力衰竭治疗中的作用和地位  

Role of Levosimendan in Therapy of Heart Failure

作　　者：葛海龙[1] 李佳[1] 富路[1] 

机构地区：[1]哈尔滨医科大学第一临床医学院心内科,哈尔滨150001

出　　处：《心血管病学进展》2005年第B08期80-82,共3页Advances in Cardiovascular Diseases

摘　　要：传统的正性肌力药物———儿茶酚胺类、磷酸二酯酶抑制剂、洋地黄制剂均通过增加细胞内cAMP和Ca2+浓度来提高心肌收缩力。而细胞内钙离子浓度的增加可引起心律失常、增加心肌耗氧。钙增敏剂———Levosimendan是不增加细胞内环磷酸腺和Ca2+的新型抗心力衰竭药物,避免了上述药物的不利作用,并且因为激活ATP敏感型钾通道而有扩血管作用。这些特性使其有望在抗心力衰竭治疗中具有可观前景。Common positive inotropic drugs catecholamines, phosphodiesterase-Ⅲ inhibitors and digoxin increased intracellular cAMP of Ca^2＋ to enhance the contractility of myocardium. An increase in intracellular calcium can lead to harmful arrhythmias and increases the energetic demands of the myocardium. Calcium sensitizer levosimendan（LS） is a new type anti-heart failure drug that exerts without increasing intracellular cAMP or Ca^2＋ at therapeutic doses. Therefore it may avoid major limitations of above positive inotropic drugs. In addtition,it has a vasodilator action due to an opening of the ATP-sensitive potassium channels. All these properties make it a highly promising agent for the treatment of patients with heart failure.

关 键 词：钙离子增敏 LEVOSIMENDAN 心力衰竭 正性肌力药 

分 类 号：R541.6[医药卫生—心血管疾病]